Q4 2011 · —
Revenue$83.54M$83.54M ±0.0% vs Q4 2010+14.0% vs Q3 2011
Net Income$37.47M$37.47M ±0.0% vs Q4 2010+15.4% vs Q3 2011
EPS Diluted$0.79$0.79 ±0.0% vs Q4 2010+14.5% vs Q3 2011
Gross Profit$77,073,000±0.0%
Operating Incomederived$37,664,000—
Operating Cash Flowderived$43,659,000+91.6%
Free Cash Flowderived$42,903,000+89.2%
Margins · derived
Gross margin92.3%±0.0 pt vs Q4 2010
Operating margin45.1%
Net margin44.9%±0.0 pt vs Q4 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q4 2011 | Q4 2010 |
|---|---|---|
| Revenue | $83.54M | $83.54M |
| Net Income | $37.47M | $37.47M |
| EPS Diluted | $0.79 | $0.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR